MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.79−0.46 (-4.09%)
Close on Nov 18, 2026Market cap $918.30MP/E –Yield –
MoonLake Immunotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MoonLake Immunotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$268.34M. For fiscal 2025 it was -$244.83M. The highest annual figure on record is -$4.57M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$244.83M | – |
| FY2024 | Dec 31, 2024 | -$143.09M | – |
| FY2023 | Dec 31, 2023 | -$54.12M | – |
| FY2022 | Dec 31, 2022 | -$65.06M | – |
| FY2021 | Dec 31, 2021 | -$4.57M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$61.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$70.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$65.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$71.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$60.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$43.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.70M | -148.1% |
| Q3 FY2022 | Sep 30, 2022 | -$14.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.94M | – |
| Q4 FY2021 | Dec 31, 2021 | $34.73M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$94.11K | – |
See a number that looks wrong?